Business Context and Reporting Period
This Form 8-K was filed by Lyell Immunopharma, Inc. on September 10, 2026. The report details a significant operational milestone regarding the Company's next-generation guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate, LYL273, intended for the treatment of relapsed/refractory metastatic colorectal cancer and other GCC-expressing cancers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational events and does not contain financial statements or quantitative financial data.
Material Changes and Operational Updates
- Technology Transfer Completion: The Company completed the technology transfer for LYL273 to its LyFE Manufacturing Facility in Bothell, Washington.
- Clinical Trial Update: An updated timeline was provided for the Phase 1/2 trial evaluating LYL273 in metastatic colorectal cancer.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the manufacturing transfer and the updated clinical trial timeline. The filing does not explicitly state new financial guidance, specific risks, contingencies, or unusual items beyond the standard operational progress of the drug candidate.
Investor Verification Checklist
- Verify the specific dates and milestones in the updated Phase 1/2 trial timeline for LYL273.
- Confirm the capacity and regulatory status of the LyFE Manufacturing Facility in Bothell, Washington, following the technology transfer.
- Review the full text of the press release (Exhibit 99.1) for detailed clinical data or safety updates not summarized in this 8-K.